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Getting it together: signal transduction in G-protein 
coupled receptors by association of receptor domains 
Dennis J Underwood and Kristine Prendergast 
The mechanism of signal transduction by G-protein 
coupled receptors is unknown. Here, we propose that 
these receptors signal in a way that is qualitatively 
similar to that seen in the chemokine and endocrine 
hormone receptor families; the signal occurs when two 
domains of the receptor are brought together, although 
this is not the only requirement for signaling. 
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Membranes provide a substantial barrier dividing the 
intracellular machinery from the surrounding extracellular 
milieu. Communication between cells and their environ- 
ment therefore requires transmission of extracellular 
signals across this barrier [1,2]. Membranes also provide a 
specialized medium for specific biological processes that 
are critical for cellular function and the composition of the 
membrane is important in determining the unique behav- 
ior and function of integral membrane proteins. The 
kinetics and thermodynamics of processes such as signal 
transduction across mernbranes, ion diffusion and active 
and passive transport are inextricably linked to the nature 
of the membrane. There are two primary reasons for this. 
First, because the core of the membrane is non-polar, the 
Figure 1 
non-specific hydrophobic interactions that drive associa- 
tions in an aqueous environment are less important, 
whereas electrostatic effects are more important. Second, 
membranes are effectively two-dimensional fluids [3,4], 
with many of the characteristics typical of liquid crystals 
[S]. Reactions involving the association of biological com- 
ponents within this environment are augmented by this 
reduction in dimension; membrane localization increases 
the rate at which the reactants encounter one another and 
restricts the orientation in which they collide. This is a 
frequently-used mechanism of increasing reaction rates, 
and often involves linking of lipids to proteins to localize 
them to (or alter their interaction with) the membrane. 
Examples include the palmitylation of G-protein coupled 
receptors (GPCRs) [6], palmitylation and myristylation of 
G-proteins [7] and farnesylation of CAAX boxes [8,9]. 
Any model of GPCR signal transduction must address the 
association of and equilibrium between agonist, antagonist 
and G-protein, as well as other factors, within the mem- 
brane environment. Our proposal is that the transduction 
of a signal has two elements. We suggest that the associa- 
tion of two domains, transmembrane (Thl) helices 1-5 
(domain I) and TM helices 6 and 7 (domain II), is necessary 
for signal transduction (see Fig. la). This is not sufficient 
for signal transduction, however; a second requirement for 
agonist activity is a specific perturbation of the conforma- 
tional states of receptor sidechains in the vicinity of the 
agonist’s binding site, followed by G-protein association. 
Mechanisms of receptor signaling. (a) Top view (extracellular) and side Transmembrane helices l-7 are labeled Hl -H7. (b) X-ray structure of 
view of a model of the GPCR Aii/ATl , showing a C, trace of domain I the soluble domain of human growth hormone receptor (hGHr) with 
(white) and domain II (red) with the non-peptide agonist L-l 62,313 hGH [13]. Two receptor molecules are shown, one in red, the other in 
(shown as a CPK model) sandwiched between them [40]. green. Between the domains is hGH (magenta). 
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Figure 2 
Description of the proposed receptor states. 
The seven TM helices are shown in blue, the 
agonist as a yellow star and the G-protein in 
majenta. A  route through this six state scheme 
that might describe the lowest free energy 
path for the signal transduction of most 
GPCRs is as follows. The first step [(a) to 
(b)] is the binding of the agonist to the 
unorganized, G-protein-free receptor; this 
step has the equilibrium constant K,,; the 
free energy of binding is given by -RT InK,, 
In the second step L(b) to (d)], a receptor that 
has already bound agonist rearranges to give 
an activated receptor. This step has the 
equilibrium constant K,,., determined by the 
free energy of association of the domains of 
the receptor. In the third step [(d) to (01, the 
G-protein binds to the activated receptor. 
KHR.G describes the AGbi,,, of the G-protein 
to the GPCR with bound agonist and with the 
receptor in the activated configuration. 
Precoupled GPCRs may follow a different 
route. The transition (a) to (c), with equilibrium 
constant K,,, may be significantly more 
favorable for precoupled receptors compared 
to non-precoupled receptors. (The ratio 
K&K,. is a measure of the efficacy of the 
agonist H for a particular receptor.) Such 
receptors may then be able to bind directly to 
G-proteins L(c) to (e)], and this state may 
represent a local min imum on the free energy agonist, and KH+R.+G the equilibrium which 
manifold for precoupled receptors. Km, then leads to binding of the agonist to the 
describes the AG,,,, of the G-protein to the precoupled receptor. Signal transduction 
activated receptor in the absence of bound occurs from state (f). 
Because of the fluidity of the membrane, GPCRs undergo 
continual and dynamic reorganization restrained only by 
receptor topology. We suggest that the receptors can 
access several metastable states which form minima on a 
complex manifold of equilibria (see Fig. 2) and visit these 
states even in the absence of G-proteins, agonists and 
other effecters. When G-proteins and agonists are present, 
however, the appropriate metastable state is stabilized, 
and it is this that leads to signal transduction across the 
membrane. The notion that signaling processes derive 
from transitions between metastable states of the receptor 
comes from studies of the light activation of rhodopsin and 
bacteriorhodopsin [lo]. It is expected that the population 
of receptor states depends on the local concentration and 
conformation of essential components such as endogenous 
ligands, G-proteins and ions. 
Domain association 
Signal transduction processes in the hematopoietic family 
of integral membrane receptors, which are composed of 
an extracellular domain, a transmembrane linkage and an 
intracellular domain, begins by association of the extracel- 
lular domains by the endogenous hormone. This leads, 
through the increased proximity of the transmembrane 
linkers, to coupling of the intracellular domains [ll]. Spe- 
cific recognition of the coupled intracellular domains by 
downstream components then initiates the signaling 
cascade [12]. Experimental evidence for these processes 
come from structural studies of human growth hormone 
receptor [13,14]. The cellular response to extracellular 
growth hormone is initiated by dimerizing the transmem- 
brane receptor (Fig. lb) to form an intracellular binding 
site for intracellular kinases of the JAK-STAT pathway 
[14]. Other receptors that transduce signals by oligomer- 
ization include the ciliary neutrotrophic factor receptor 
[ 151, the epidermal growth factor receptor family [ 161, the 
insulin receptor family, the colony stimulating. factor 
receptor family, the endocrine hormone receptor family 
and the cytokine receptor family [ 17-191. 
By analogy, we propose that GPCR signal transduction 
occurs by the association of two tethered domains, domain 
I and domain II. As well as stabilizing the association of 
these two domains, agonists perturb specific conforma- 
tional states of receptor sidechains in the vicinity of their 
binding sites. This change in conformation is communi- 
cated to the cytoplasmic site at which the G-protein binds 
to the receptor. The G-protein binding site includes the 
cytoplasmic loop linking TM5 and TM6 (the third cyto- 
plasmic, C3, loop), and parts of the carboxy-terminal 
domain (the C4 loop), and is formed by the association of 
TM.5, TM6 and TM7 as domains I and II come together. 
Again, the formation of this site and binding of the 
G-protein is dependent on the levels of agonist (and 
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Figure 3 
A schematic showing the topology of the 
receptor domains. The seven helical domains, 
labeled l-7, are joined by a series of variable 
length loops. These are labeled according to 
their location: E, extracellular and C, 
cytoplasmic. Domain I is defined as helices 
l-5 and domain II as helices 6 and 7. 
Extracellular 
Intracellular 
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antagonist), GTP, monovalent and divalent ions and, 
importantly, the conformational state of the receptor. 
Agonist and antagonist binding sites are accessible from 
the extracellular milieu and occupation of these sites 
affects the distribution of GPCR states. 
Topological definition of receptor domains 
GPCR topology suggests that the seven helical domains 
are tethered by a series of variable length loops (see 
Fig. 3) [ZO]. These are involved in arranging and con- 
straining the seven helices and, for the cytoplasmic loops, 
providing part of the binding site for the G-protein 
trimer. For some GPCRs, the extracellular loops have 
been identified as contributing to the agonist binding 
site. The loops joining TM1 to TM2 (Cl loop), TM2 to 
TM3 (the second extracellular, E2, loop) and TM3 to 
TM4 (C2 loop) are generally short to medium length. A 
conserved disulfide bond linking the top of TM3 to the 
third extracellular (E3) loop at the amino-terminal end of 
TM5 appears to be important for receptor folding and 
function, however [6]. We define TMl-5 as domain I in 
our model. 
The loop that joins domain I to domain II, C3, is of vari- 
able length, and is known to be critical for receptor func- 
tion. The C3 and C4 loops are both known to be involved 
in G-protein binding [21-241. The E4 loop between TM6 
and TM7 is also short to medium in length. In our model 
the extracellular loops El3 (domain I) and E4 (domain II) 
are in close proximity. Both of these loops contain compo- 
nents that contribute to agonist binding in at least one 
tachykinin receptor subtype [ZS]. 
Changes in topology do not affect function 
Studies show that the functional integrity of GPCRs can be 
maintained even after removing certain structural con- 
straints. For bacteriorhodopsin, which belongs to the super- 
family of seven helix integral membrane proteins but 
which is not coupled to G-proteins, the loop connecting the 
segment AB (TMl,Z) to CDEF (TM3-7) can be deleted 
without significantly altering receptor function [26]. Kahn 
and coworkers [27] fragmented bacteriorhodopsin and 
measured the change in the thermodynamic stability with 
respect to retinal binding, finding that the loop structure is 
not necessary to constrain the helices into a functional 
receptor. More dramatically, Lefkowitz and coworkers [28] 
generated functional, split BZ-adrenergic receptors by sepa- 
rately expressing TMl-5 and TM6,7 in the same cell. The 
split receptor bound agonists and antagonists normally, and 
showed 25% of the activity of wild-type in activation of 
adenylyl cyclase. Thus, the two segments of the receptor 
can recombine in the presence of agonist to form a func- 
tional, complete receptor. Wess and coworkers [29-311 also 
reconstituted functional receptors from expression systems 
which produce mixtures of TMl-5 and TM6,7 domains 
from different muscarinic receptors (M,, M,) and from a 
mixture of the muscarinic and adrenergic receptors (R/I,, 
‘Y*) with similar success. These results suggest that the 
helices of GPCRs have a natural order and a tendency to 
associate and signal normally even when the structural 
tether restricting diffusion is broken. 
Defining a domain interface: through mutagenesis 
Site-directed mutagenesis has provided evidence that a 
highly conserved acid residue on TM2, involved in Na+ 
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regulation, is close to a conserved hydrophilic patch on 
TM7: both sites are implicated in signal transduction 
[32-341. Mutation of TM2 Asp79+Asn in the oZa receptor 
interrupts signal transduction with minimal impact on 
agonist binding [35]. The angiotensin-ii, AT1 subtype 
receptor (Aii/ATl) mutations Tyr292-+Phe and Asn298+ 
Ala in TM7 indicate that these residues are involved in 
signal transduction; agonist and antagonist binding are not 
affected but the coupling to phospholipase C is impaired 
[32,33]. In addition to the TM2 and TM7 interface 
between domains I and II, TM5 and TM6 also provide 
the interface between domain I and domain II. For 
example, Tyr205 (TMS) in addition to Glu78 (TMZ) have 
been shown to be involved in receptor activation in the 
neurokinin-1 receptor (NKl) [36]. In the gonadotropin 
releasing hormone (GnRH) receptor the conserved acid 
described above is found in TM7 (residue Asp318) [37]. If 
either Asn87 (TMZ) or Asp318 (TM7) are mutated in 
GnRH, the ligand-binding activity of the receptor is 
destroyed; but swapping these two residues gives a recep- 
tor that can bind ligand, but not signal [38]. Further evi- 
dence that TM2 and TM7 interact comes from the 
observation that muscarinic receptor chimeras were func- 
tional only when TM2 and TM7 were from the same 
subtype [39]. All of these mutations are found at the inter- 
face between domain I and domain II and their effect on 
signal transduction imply that contact between these 
domains is essential. 
Location of the ligand and G-protein binding sites 
The footprint of a minimal ligand binding site defined by 
residues from both domain I and domain II is spatially 
conserved in a number of GPCR families [6,40,41]. 
Specifically, for the l3Z adrenergic receptor Phe290 (TM6) 
and SerZ04 and Se207 (TMS) interact with agonists and 
are required for activating the receptor [42-441. For larger 
peptide and protein agonists, the binding site often 
extends to TM1 and TM2 [6,45,46] or to extracellular 
loop regions [47] but still preserves contacts with the 
TM domains. 
The third cytoplasmic loop ((23) joining TM5 and TM6 is 
important in both signal transduction and G-protein 
binding [21,22,24]. If the C3 loop of the orb receptor is 
exchanged for that of PZ, both receptors become constitu- 
tively active [21,22,24]. The Leu194+Gln mutation in the 
C3 loop for the Ste3 receptor also causes constitutive activ- 
ity [23,48]. These studies suggest that the C3 loop is a 
negative regulatory domain: mutant loops fail to inhibit 
G-protein binding, resulting in a G-protein-receptor com- 
plex with a permanent high affinity agonist binding state. 
(The secretin class of receptors appears to be more compli- 
cated: large portions of both the C3 and the C4 loops can 
be deleted without affecting G-protein binding and signal 
transduction [49].) The structural role of this loop in 
G-protein activation is highlighted by studies of the circu- 
lar dichroism spectra of free peptides derived from the C3 
loop of p receptors. These helical peptides have been 
shown to activate the G-protein Gs [SO]. Further evidence 
for the involvement of the C3 loop in signal transduction 
comes from work identifying Tyr254 (C3) as critical for 
GPCR coupling to the phosphatidyl inositol signaling 
pathway in muscarinic receptors [Sl]. This residue is con- 
served among many different classes of GPCR and com- 
municates with the conserved ‘aromatic girdle’ implicated 
in agonist binding and signal transduction [40]. 
The observation that the C3 loop, identified above as 
comprising the G-protein binding surface, connects the 
TM5 and TM6 helices, which are both involved in ligand 
binding (Fig. la), is important because it suggests a direct 
mechanism for signal transduction. Extracellular ligand 
binding events will result in a change in the way that the 
helical rods of the receptor associate, and this can be 
directly communicated to the intracellular G-proteins 
through the C3 loop. Conversely, G-protein binding to its 
intracellular site favors agonist binding. 
A minimal model for signal transduction 
Precoupled receptors (receptors that have a high affinity for 
the G-protein in the absence of agonist) have been identi- 
fied by a battery of experimental approaches (Table 1) 
[47,52-571. Examples of receptors showing significant pre- 
coupling include the CSa receptor, the adenosine Al recep- 
tor (85-90% precoupled [52]), platelet o2 receptor (30% 
precoupled [52]), cxZB adrenergic receptor (40% precoupled 
[53]) and D’2 dopamine receptor (40-50% precoupled [SZ]). 
The existence of precoupled GPCRs underscores the 
importance of including G-protein interactions in mecha- 
nistic schemes of signal transduction. There has been 
much discussion about the two-state receptor model in 
the recent literature [58-621. Only two states of the recep- 
tor are considered in this model; the activated state from 
which signal transduction occurs (R”) which is in equilib- 
rium with the resting state (R). In this model agonists 
bind and increase the population of the activated state. 
Antagonists drive the equilibrium toward the resting state 
of the receptor. This description provides a rationale for 
agonist and antagonist binding but ignores the contri- 
bution of G-protein binding to the thermodynamics of 
ligand binding. 
Figure 2 shows a hypothetical set of equilibria between 
receptor, G-protein and hormone. In this model, agonist or 
antagonist and G-protein can bind independently to the 
receptor and stabilize various receptor states including the 
activated state (R”; see Fig. 2d and Fig. Ze, respectively). 
The underlying preference of G-proteins for different 
states of the receptor is governed by complex equilibria, 
but the whole set of equilibria reduces to the two-state 
model when individual interactions between the hormone 
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Table 1 
Observation of precoupled states. 
Experimental methods Observations Mechanism of action and state probed 
Kinetics [55,571 
Isolation of R*G [47,561 
Chemical cross-linking 
between R and G [53,54] 
GTP, Gpp(NH)p and 
GTPyS effects [52,53] 
Na+ and monovalent 
cation effects 134,52,53,801 
Effects of toxins (PTX, CTX) [53] 
Functional effects by 
antagonists [53,81] 
Data fits H*R*G kinetic models. Implies R*G, precoupled states. 
Co-purification of G-protein with the 
receptor in the absence of agonists. 
Receptors having intrinsic affinity for G-proteins achieve 
precoupled states depicted in Fig. 2e. 
EGS is a reagent which cross-links lysine 
residues. Antagonists, GTP analogs and 
Na+ protect against cross-linking. 
Negative antagonists, inverse agonists and insurmountable 
antagonists bind to inactivated receptor (Fig. 2a,b) and 
thereby shift the equilibria away from activated states 
(Fig. 2c-f). GTP analogs dissociate G-protein 
heterotrimers (these equilibria are not shown in Fig. 2) 
thereby reducing the population of states represented by 
Fig. 2e,f). 
GTP and non-hydrolyzable analogs bind 
to Go subunits. These reagents 
decouple the receptor from the G-protein 
and thus decrease the binding affinity of 
agonists. 
Na+ decouple receptors from the 
signal transduction events. Na+ ions 
cause a concentration dependent 
decrease in agonist affinity. 
Decouple the receptor from the 
signaling pathway. Diminishes agonist 
high affinity binding. 
Addition of antagonists can stimulate 
CAMP production if the receptor 
couples through Gi. 
Probes high affinity (Fig. 2e,f) and low affinity agonist 
states (Fig. 2a,b, the folded receptor, and Fig. 2c,d, 
the unfolded receptor) of the receptor. GTP analogs 
dissociate G-protein heterotrimers these equilibria are not 
shown in Fig. 2) thereby reducing the population of states 
represented by Fig. 2e,f). (GTP analogs protect receptors 
from EGS cross-linking. 
Monovalent ions reduce the stability of the precoupled 
states through a mechanism which is G-protein 
independent. The conserved TM2 acid has been shown to 
be the likely site of this interaction. Na+ protect receptors 
from EGS cross-linking. 
Toxins cause ADP-ribosylation of a conserved residue 
in the carboxy-terminal tail of Go (Cys in PTX and an Arg in 
CTX). Thus they suppress (but may not eliminate) 
precoupling between R and G. Their effect therefore is to 
diminish states precoupled states such as Fig. 2e,f. 
The basal activity of receptors (absence of agonist) must 
occur through a coupled R.G complex (through Fig. 2e but 
not via 2f). Precoupled receptors inhibiting CAMP through 
Gi will show stimulation of CAMP with antagonists which 
diminish precoupled states. 
Gpp(NH)p, 5’-guanvlvlimidodiphosphate; GTP+, guanosine-5’-O-(3thiotriphosphate); PTX, pertussis toxin; CTX, cholera toxin; EGS, ethylene 
gly&ol bis(succ~nimibyl)succinate; iAMP, cyclic’AM-P. 
and G-protein with the receptor are ignored. Without 
these interaction the only relevant states are R and R’ and 
K,, is modulated by agonist and antagonist binding. From 
the previous discussion of precoupled receptors, it is clear 
that the interactions between the receptor and G-proteins 
are critical, however. 
Even the complexity of Figure 2 represents a simplifica- 
tion of the true physiological situation: there are many 
other factors that are not shown in this model. The popu- 
lation of a given state depends on the details of the inter- 
action between the ligand, receptor and G-protein, not to 
mention environmental factors such as ionic strength, 
nucleotide concentrations (GDP and GTP) and mem- 
brane factors. Further, each receptor will have a different 
propensity for association with the G-proteins available in 
the particular tissue in which it is found [35,63]. Consider- 
ing the complexity of factors, it is no surprise that the 
pharmacology for GPCRs is so rich. 
Thermodynamic analysis of receptor states 
The BZ receptor is not precoupled under most conditions, 
and so it is clear that the ‘ground’ state of this system does 
not involve tight association between the receptor and 
G-protein. In terms of the simple hypothesis of domain 
association outlined above, signal transduction in the B2 
receptor requires binding of an agonist, organization of the 
helical domains to provide a G-protein binding site 
(Fig. Zc), binding of the relevant G-protein and allosteric 
communication between the agonist and the nucleotide 
binding site. Enthalpy-entropy compensation studies with 
the BZ receptor indicate that AH correlates linearly with 
TAS for a number of agonists, partial agonists and antago- 
nists [64-661 (see also Gilli et al. [67]). This is expected 
since entropy-enthalpy compensation is a general phe- 
nomenon for ligand-receptor and enzyme binding. But 
the binding of agonists, partial agonists and antagonists 
to the BZ receptor occurs with different compensatory 
effects (Fig. 4a). Under certain conditions, agonists bind to 
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GPCRs with a large negative enthalpy change (AHbind) 
resulting in a favorable free energy of binding (AGbind); the 
entropy contrrbutron (TASbind) is unfavorable (AGbind = 
AH - TAS). The balance between favorable enthalpy and 
unfavorable entropy results from tight evolution of optimal 
interactions between the receptor and the endogenous 
agonist. The unfavorable entropy observed for agonist 
binding to PZ is characteristic of an increase in the overall 
organization of the system. Antagonists, on the other hand, 
interact less tightly with less favorable AHbind and pay 
less of an entropic penalty. Partial agonists fall between 
agonists and antagonists in entropy cost (Fig. 4a) [65,66]. 
The thermodynamic information for &? adrenergic recep- 
tors in membranes indicate that antagonist binding is tem- 
perature independent and entropy driven; this means that 
AG is approximately equal to AH, and TAS is constant 
[68]. Agonist binding, on the other hand, is temperature 
dependent and enthalpy driven, so AG = AH - TAS. For 
the high affinity state of the receptor, or in the absence of 
GTP, there is a large decrease in TAS. A large decrease in 
entropy is expected for a process which requires an 
increase in organization of the system such as the associa- 
tion of agonist, receptor and G-protein (steps described by 
KR*G and KH+R*G shown in Fig. 2). For the low affinity 
state of the receptor, agonist binding has only a slight 
temperature dependence. This result is similar for agonist 
binding in the presence of GTP (the G-protein-decou- 
pled states described by equilibria K”R and KH+RX; 
Fig. 2). The smaller decreases in TAS for agonist binding 
to the low affinity state or the GTP decoupled state 
reflect conformational effects that communicate agonist 
binding to the G-protein. Similar experiments were per- 
formed with solubilized receptor in the absence of 
G-protein [69]. 
In contrast to the results above, some recent thermody- 
namic data on the low and high affinity binding states of 
the @? receptor indicate that binding of both agonists and 
antagonists is driven by entropy [70]. But these experi- 
ments were performed using tissue-derived cells, not iso- 
lated membranes or soluble receptors, and so differences 
in membrane composition, cellular components and assay 
conditions may have influenced these results. 
Thermodynamic analysis of precoupled receptors 
For receptors which have a natural predisposition to fold 
or preorganize and which are precoupled to G-protein, 
the binding of agonist does not incur unfavorable entropy 
changes; for example, the adenosine Al receptor. Note 
however, there are still entropic costs of ligand binding 
and complex changes in solvent organization which will 
have entropic effects. Nonetheless, the entropic contribu- 
tions for the precoupled versus the non-precoupled 
receptors are expected to be different as explained. An 
example of a precoupled receptor is the adenosine Al 
Figure 4 
(a) p2 Adrenergic receptor 
0. 
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-50 I 
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The thermodynamics of ligand binding are altered in precoupled 
receptors. (a) Graph of the enthalpy versus entropy for a number of 
agonists, partial agonists and antagonists of the f32 adrenergic 
receptor, a receptor that is not precoupled to a G-protein. (b) Graph of 
the enthalpy versus entropy for a number of agonists, partial agonists 
and antagonists of the adenosine Al receptor, which is a precoupled 
receptor. 
receptor [SZ]. In its native state, the adenosine Al recep- 
tor has a quite different thermodynamic profile from the 
PZ adrenergic receptor, showing entropy-driven agonist 
binding and enthalpy-driven antagonist binding (compare 
Fig. 4a with Fig. 4b) [67]. But when the receptor is 
decoupled from the G-protein, its enthalpy-entropy 
profile becomes similar to that of PZ [71]. Thus, an analy- 
sis of receptor interactions with G-proteins is essential to 
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understanding the thermodynamic data for precoupled 
receptors (Fig. 2). 
Ligand-mediated signal transduction requires a specific 
association of receptor, agonist and the G-protein. Basal 
level activity occurs in the absence of ligand and is depen- 
dent on factors such as receptor reserve (total number of 
available receptors). The basal activity of precoupled 
receptors is higher than for non-precoupled receptors [52]; 
for receptors that are not precoupled the affinity of the 
receptor for the G-protein in the absence of agonist is low. 
Precoupled receptors also appear to be less discriminating 
toward ligands. These receptors accept more ligands as 
agonists, and the more tightly G-protein-associated recep- 
tors are also the more promiscuous. These results suggest 
that the necessary (but not sufficient) condition of associa- 
tion of domains I and II by the G-protein imparts less 
stringency on agonist recognition by the receptor. 
Both basal activity and constitutive activity [24] are 
agonist independent: agonists are not required to mediate 
activation and encounters between the activated recep- 
tor R” and the G-protein (Fig. 2e result in GDP/GTP 
exchange and signal transduction. One method for gener- 
ating constitutively active receptors is to disrupt the 
inhibitory function of the C3 loop, thereby allowing the 
G-protein to bind and promote formation of the activated 
state of the receptor (R*, Fig. Zc,e) giving an activated 
receptor complex primed for signal transduction. The pre- 
coupled state shown in Figure 2e provides a common 
structure for understanding phenomena such as basal 
activity, precoupled receptor promiscuity and constitu- 
tively active receptors. These phenomena can be consid- 
ered as resulting from small structural and conformational 
changes brought about by mutations and deletions and by 
changes in environmental conditions that perturb the 
equilibria between the different receptor states. The 
manner in which these changes alter the landscape of 
free-energy peaks and valleys which describe this system 
of receptor, ligand and G-protein is subtle, complex and 
difficult to predict; nonetheless, the stabilization of differ- 
ent receptor states has a direct and profound effect on 
receptor pharmacology. 
The six-state model helps explains receptor pharmacology 
The two-state model of receptor activation does not 
explain the above phenomena in a satisfactory way. The 
simple model that the receptor can be either in the resting 
or unactivated state (R) or the activated state (R”) offers 
no explanation for the distinct behavior of precoupled 
receptor states. Similarly, a four-state model which consid- 
ers only the interaction with hormones (Fig. Za-d) cannot 
account for precoupled states involving G-proteins. The 
simplest model that includes G-protein interactions is the 
six-state model depicted in Figure 2. We believe that 
Figure 2 provides a useful model of GPCR activation 
processes and helps clarify much of the pharmacology of 
agonists and antagonists. 
The complexity of these interactions is reflected in the 
richness of ligand pharmacology. Ligands can display 
agonism, partial agonism, balanced, insurmountable and 
negative antagonism, or inverse agonism. It has been 
argued that the phenomenon of inverse agonists supports 
the two state model of receptor activation [72,73]. In our 
model inverse agonists sequester the receptor in states 
that are unable to bind and/or activate G-proteins; these 
states are represented by Figure 2b. This results in dimin- 
ished basal activity of the receptor, the hallmark of inverse 
agonism. The difference between insurmountable antago- 
nists, negative antagonists and inverse agonists may lie 
more in the degree to which they affect distribution of 
conformational states within the thermodynamic manifold 
of the receptor than in grossly different mechanisms of 
action. For example, ligands that exhibit insurmountable 
antagonism may have slow off rates [52,53], again seques- 
tering the receptor in states that cannot be rescued by 
addition of agonist [74]. Antagonists can protect against 
receptor-G-protein cross-linking reagents such as ethyl- 
ene glycol bis(succinimidy1) succinate (EGS; see Table 1) 
[53,54]. For antagonists, a small k,, perturbs equilibria 
and stabilizes states which are non-productive toward 
signal transduction. Thermodynamics are governed by the 
law of mass action: the k,, for dissociation of an antagonist 
from the receptor is much smaller than the k,, for the 
agonist [75]. Receptors locked in these states (similar to 
the states shown in Fig. Zd,e) may present pharmacology 
typical of insurmountable antagonists and inverse agonists. 
Consequences for ligand design 
Precoupled receptors have a greater propensity for signal 
transduction and are readily activated by a greater range 
of ligands. The key outcome of agonist binding to its 
receptor is the stabilization of a receptor state that pro- 
vides a binding site for the G-protein and activates it. 
Agonist and G-protein binding are cooperative. There are 
two primary prerequisites for agonism: ligands must have 
the necessary functionality with the appropriate chirality, 
and this functionality must be presented to the receptor 
in a manner specific for receptor activation. Antagonists 
can prevent a functional response of the receptor in a 
number of ways: by blocking agonist binding either by 
partial or full overlap with the agonist binding site (a 
direct spatial effect) or blocking the binding site; by 
blocking agonist binding through a conformational or 
allosteric effect on the receptor (an indirect effect); by 
interfering directly with the mechanism of signal trans- 
duction rather than blocking agonist binding; and by sta- 
bilizing conformational states of the receptor which are 
sequestered from interaction with agonists. Each of these 
mechanisms provide opportunities to block the functional 
response of the receptor. A successful strategy is to design 
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antagonists which bind at the same site as agonists and 
block the receptor by being unable to present the 
required arrangement of functionality required for signal 
transduction. For example, the required functionality can 
be modified to prevent activation but not binding, or the 
required geometry for interaction can be destroyed by 
inverting chirality or blocking appropriate conformations. 
In either case, balancing potency and selectivity while 
eliminating agonism can be a challenge. The issue of 
antagonist development for highly precoupled receptors 
is more problematic and the strategies are less well devel- 
oped; the window for achieving antagonism is often small 
and requires drastic measures such as changing the 
important stereochemistry of an endogenous agonist or 
changing the fold of the ligand [76]. Indeed, the struc- 
tural diversity typical for antagonists may not be apparent 
for precoupled receptors. Eliminating agonism within a 
non-peptide drug discovery effort has not always been 
easy to achieve [40,77-791. 
It is not clear how similar our proposal for signal transduc- 
tion in GPCRs is to that for endochrine hormone and 
cytokine receptors. It would be satisfying and reassuring 
to know that there is a common mechanism for signal 
transduction through the cellular membrane for these 
very different receptor types and that these similarities 
were reflected in the thermodynamics. This similarity 
suggests that the range of receptor pharmacology seen 
with GPCRs might also be available for the endochrine 
hormone and cytokine receptors: agonism, partial 
agonism, balanced, insurmountable and negative 
agonism, and, perhaps, inverse agonism. The key ele- 
ments of our hypothesis involve receptor folding and the 
conformational perturbation of receptor states on agonist 
binding as necessary and sufficient events for signal trans- 
duction. These processes suggest a number of experimen- 
tal approaches to defining the mechanism of signal 
transduction in GPCRs: domain linking which couples 
the receptors in their activated state has been used to 
demonstrate the need for domain association. The pertur- 
bation of conformational states occurring with agonist 
binding could be studied using fluorescent or paramag- 
netic probes which are sensitive to the ordering of the 
receptor. It is also possible that the more stable of the 
receptor states can be detected and differentiated using 
biological probes such as antibiotics. If our model is 
correct, it will have significant ramifications for the design 
and discovery of ligands as therapeutic agents, especially 
for receptors that are precoupled to G-proteins. We 
predict, for example, that it will be relatively simple to 
find agonists for such receptors but much more difficult to 
find antagonists. The state of a given receptor will also 
affect its propensity for signal transduction of receptors 
and its sensitivity to changes in assay conditions; such con- 
siderations will clearly be important in the development 
of meaningful assays. 
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